Teligent is a specialty generic pharmaceutical company (NASDAQ: TLGT). Our mission is to be a leading player in the specialty generic prescription drug market.
We have 16 Abbreviated New Drug Applications (ANDAs) on file at the FDA, representing a total addressable market of approximately $1.4 billion (IQVIA, April 2019).
We sell a portfolio of prescription topical medicines and a growing number of hospital-based sterile injectable products, including cephalosporins.
"We are forging the path to profitable growth and will continue to make the tough decisions needed to grow this business responsibly."
Teligent, Inc. Announces Second Quarter 2020 Results
BUENA, N.J. , Aug. 19, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pha...Learn More
Teligent, Inc. to Hold Conference Call for Second Quarter 2020 Financial Results and Business Update on Wednesday August 19th, 2020
BUENA, N.J. , Aug. 14, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pha...Learn More
Teligent Announces Completion of Series C Convertible Note Financing and Exchange
BUENA, N.J. , July 20, 2020 (GLOBE NEWSWIRE) -- Teligent , Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jers...Learn More